Karp, Judith E <br/><br/>
Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.  [electronic resource] 

 -  Leukemia research  Jul 2010 
 - 877-82 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1873-5835 
<br/><br/><label>Standard No.: </label>10.1016/j.leukres.2009.11.007  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Allopurinol--therapeutic use<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bone Marrow Transplantation<br/>Combined Modality Therapy<br/>Cytarabine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Flavonoids--administration & dosage<br/>Follow-Up Studies<br/>Heart Diseases--chemically induced<br/>Humans<br/>Hyperkalemia--chemically induced<br/>Kaplan-Meier Estimate<br/>Leukemia, Myeloid, Acute--drug therapy<br/>Male<br/>Middle Aged<br/>Mitoxantrone--administration & dosage<br/>Piperidines--administration & dosage<br/>Polyamines--therapeutic use<br/>Premedication<br/>Remission Induction<br/>Risk<br/>Sepsis--etiology<br/>Sevelamer<br/>Transplantation, Homologous<br/>Treatment Outcome<br/>Tumor Lysis Syndrome--etiology<br/>Young Adult